相关实验视频

Updated: Jun 29, 2025

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

抗R-tPA是特定于富有血小板的中风血栓,可以通过向非纤维素成分来克服

Sarah Vandelanotte¹, Olivier François², Linda Desender¹

¹Laboratory for Thrombosis Research, KU Leuven Kulak, Kortrijk, Belgium (S.V., L.D., S.S., C.T., K.V., S.F.D.M.).

|March 25, 2024

概括

脑卒中血栓的组成决定了对复合组织类型等离子体激活剂 (r-tPA) 的耐药性. 缺乏红细胞的血栓是耐药的,但可以通过将r-tPA与DNase-1或N,N'-diacetyl-l-cystine结合而溶解.

科学领域:

生物医学研究的研究.
血栓形成和血液静止.
缺血性中风治疗治疗缺血性中风治疗

背景情况:

重组组织类型等离子体激活剂 (r-tPA) 耐药性是急性缺血性中风治疗的一个重大挑战.
了解血栓的组成对于改善再通道化率至关重要.
患者衍生的血栓提供了一个临床相关的模型来研究血栓溶解耐药性.

研究的目的:

为了研究血栓组成对急性缺血性中风中的r-tPA疗效的影响.
探索新的策略,以克服中风中的r-tPA抵抗.
为了将组织学血栓特征与溶解易感性相关联.

主要方法:

对来自患者的急性缺血性中风血栓的分析.
血栓组合的组织学检查 (红细胞,DNA,·维勒布兰德因子).
在试验室中使用r-tPA单独或与DNase-1或N,N '-diacetyl-l-cystine结合进行血栓溶解试验.

主要成果:

血栓溶解疗效与血栓组成有很强的相关性.
富含红细胞和低DNA/von Willebrand因子的瘤被r-tPA有效地溶解.
低红细胞和高DNA/von Willebrand因子含量的血栓对r-tPA表现出耐药性.

结论:

脑卒中血栓的组成是r-tPA介导的血栓溶解的一个关键决定因素.
缺乏红细胞的血栓对r-tPA.表现出特殊的抵抗力.
与DNase-1或N,N' - 亚基-l-cystine的联合治疗有效地克服了这些血栓中的r-tPA耐药性.

关键词:

纤维溶解是一种纤维溶解.缺血性中风中风塑原体是一种塑原体.血栓溶解药物治疗的方法 ·威勒布兰德因素是什么

更多相关视频

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...